<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35524184</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>10</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>10</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1471-2407</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>22</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>06</Day>
            </PubDate>
          </JournalIssue>
          <Title>BMC cancer</Title>
          <ISOAbbreviation>BMC Cancer</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Maintenance Therapy with Aromatase Inhibitor in epithelial Ovarian Cancer (MATAO): study protocol of a randomized double-blinded placebo-controlled multi-center phase III Trial.</ArticleTitle>
        <Pagination>
          <StartPage>508</StartPage>
          <MedlinePgn>508</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">508</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12885-022-09555-8</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">A high percentage of epithelial ovarian cancers (EOC) express the estrogen receptor (ER), which is an ideal target for endocrine therapy. Letrozole is a proven, potent aromatase inhibitor, extensively tested and used in the treatment of ER positive breast cancer. In addition, it seems a potent drug for patients with heavily pre-treated OC as demonstrated in several distinctive settings. However, it has never been evaluated prospectively in a maintenance setting for ovarian cancer after standard of care. The here proposed trial aims to define a population of EOC patients, who would benefit from the effectiveness of the generic agent letrozole, with little expected toxicity and thus beneficial impact on overall quality of life (QoL).</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">In this international multicenter randomized, placebo-controlled phase III trial at clinical centers in Switzerland, Germany and Austria, we plan to include 540 patients with primary, newly diagnosed FIGO Stage II to IV and histologically confirmed low- or high-grade serous or endometrioid epithelial ovarian/fallopian tube/peritoneal cancer. Patients are randomized in a 1:1 ratio into two groups: receiving blinded study treatment (letrozole or placebo tablets). When assuming a HR of 0.7, a median PFS of 18 months in the control arm and a median PFS of 25.7 months in the treatment arm, a two-sided alpha level of 5%, 3.5 years recruitment and 1.5 years observation time, we expect 330 events to have occurred within these 5 years in the total cohort yielding a power of 90%. Follow-up data for the whole cohort will be collected for up to 10 years and for the low-grade cancer for up to 12 years.</AbstractText>
          <AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">The here proposed randomized phase III trial aims to identify patients with EOC in the maintenance setting, who benefit from the effectiveness of the letrozole, by proving its efficacy whilst maintaining a high standard of QoL due to the limited toxicity expected in comparison to the current alternative drugs on the market for this treatment phase.</AbstractText>
          <AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">This trial is registered at clinicaltrials.gov under the identifier NCT04111978 . Registered 02 October 2019.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>McLaughlin</LastName>
            <ForeName>Pamela M J</ForeName>
            <Initials>PMJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gynecology and Gynecologic Oncology, University Hospital Basel, Basel, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Klar</LastName>
            <ForeName>Maximilian</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gynecology and Gynecologic Oncology, University Hospital Freiburg, Freiburg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zwimpfer</LastName>
            <ForeName>Tibor A</ForeName>
            <Initials>TA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gynecology and Gynecologic Oncology, University Hospital Basel, Basel, Switzerland.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Biomedicine, University and University Hospital Basel, Basel, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dutilh</LastName>
            <ForeName>Gilles</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Research, Clinical Trial Unit, University of Basel Hospital, Basel, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vetter</LastName>
            <ForeName>Marcus</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Hematology and Immunotherapy, Cantonal Hospital Baselland, Medical University Hospital, Liestal, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Marth</LastName>
            <ForeName>Christian</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gynecology and Gynecologic Oncology, University Hospital Innsbruck, Innsbruck, Austria.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>du Bois</LastName>
            <ForeName>Andreas</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>KEM: Evangelische Kliniken Essen Mitte, Essen, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schade-Brittinger</LastName>
            <ForeName>Carmen</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Coordinating Center for Clinical Trials, Philipps University Marburg, Wiesbaden, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Reuss</LastName>
            <ForeName>Alexander</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Coordinating Center for Clinical Trials, Philipps University Marburg, Wiesbaden, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bommer</LastName>
            <ForeName>Claudine</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gynecology and Gynecologic Oncology, University Hospital Basel, Basel, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kurzeder</LastName>
            <ForeName>Christian</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gynecology and Gynecologic Oncology, University Hospital Basel, Basel, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Heinzelmann-Schwarz</LastName>
            <ForeName>Viola</ForeName>
            <Initials>V</Initials>
            <Identifier Source="ORCID">0000-0002-4056-3225</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Gynecology and Gynecologic Oncology, University Hospital Basel, Basel, Switzerland. viola.heinzelmann@usb.ch.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Biomedicine, University and University Hospital Basel, Basel, Switzerland. viola.heinzelmann@usb.ch.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>ClinicalTrials.gov</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>NCT04111978</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <PublicationTypeList>
          <PublicationType UI="D000078325">Clinical Trial Protocol</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>06</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>BMC Cancer</MedlineTA>
        <NlmUniqueID>100967800</NlmUniqueID>
        <ISSNLinking>1471-2407</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047072">Aromatase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>7LKK855W8I</RegistryNumber>
          <NameOfSubstance UI="D000077289">Letrozole</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D047072" MajorTopicYN="N">Aromatase Inhibitors</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001943" MajorTopicYN="Y">Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077216" MajorTopicYN="N">Carcinoma, Ovarian Epithelial</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017326" MajorTopicYN="N">Clinical Trials, Phase III as Topic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077289" MajorTopicYN="N">Letrozole</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015337" MajorTopicYN="N">Multicenter Studies as Topic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010051" MajorTopicYN="Y">Ovarian Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Aromatase Inhibitor</Keyword>
        <Keyword MajorTopicYN="N">Generic</Keyword>
        <Keyword MajorTopicYN="N">Hormone therapy</Keyword>
        <Keyword MajorTopicYN="N">Letrozole</Keyword>
        <Keyword MajorTopicYN="N">Maintenance therapy</Keyword>
        <Keyword MajorTopicYN="N">Ovarian Cancer</Keyword>
        <Keyword MajorTopicYN="N">Quality of life</Keyword>
        <Keyword MajorTopicYN="N">Randomized controlled phase III trial</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that they have no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>6</Day>
          <Hour>23</Hour>
          <Minute>53</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35524184</ArticleId>
        <ArticleId IdType="pmc">PMC9074273</ArticleId>
        <ArticleId IdType="doi">10.1186/s12885-022-09555-8</ArticleId>
        <ArticleId IdType="pii">10.1186/s12885-022-09555-8</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>González-Martín A, Pothuri B, Vergote I, DePont CR, Graybill W, Mirza MR, McCormick C, Lorusso D, Hoskins P, Freyer G, et al.  Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2019;381(25):2391–2402. doi: 10.1056/NEJMoa1910962.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1910962</ArticleId>
            <ArticleId IdType="pubmed">31562799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ray-Coquard I, Cibula D, Mirza MR, Reuss A, Ricci C, Colombo N, Koch H, Goffin F, González-Martin A, Ottevanger PB, et al.  Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer. Int J Cancer. 2020;146(2):439–448. doi: 10.1002/ijc.32606.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.32606</ArticleId>
            <ArticleId IdType="pubmed">31381147</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoneoka Y, Ishikawa M, Uehara T, Shimizu H, Uno M, Murakami T, Kato T. Treatment strategies for patients with advanced ovarian cancer undergoing neoadjuvant chemotherapy: interval debulking surgery or additional chemotherapy? J Gynecol Oncol. 2019;30(5):e81. doi: 10.3802/jgo.2019.30.e81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3802/jgo.2019.30.e81</ArticleId>
            <ArticleId IdType="pmc">PMC6658596</ArticleId>
            <ArticleId IdType="pubmed">31328461</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, et al.  Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2018;379(26):2495–2505. doi: 10.1056/NEJMoa1810858.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1810858</ArticleId>
            <ArticleId IdType="pubmed">30345884</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, Fujiwara K, Vergote I, Colombo N, Mäenpää J, et al.  Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. N Engl J Med. 2019;381(25):2416–2428. doi: 10.1056/NEJMoa1911361.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1911361</ArticleId>
            <ArticleId IdType="pubmed">31851799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lorusso D, Maltese G, Sabatucci I, Cresta S, Matteo C, Ceruti T, D'Incalci M, Zucchetti M, Raspagliesi F, Sonetto C, et al.  Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile. Target Oncol. 2021;16(1):59–68. doi: 10.1007/s11523-020-00780-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11523-020-00780-4</ArticleId>
            <ArticleId IdType="pmc">PMC7810645</ArticleId>
            <ArticleId IdType="pubmed">33369704</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp A, Scambia G, et al.  Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10106):1949–1961. doi: 10.1016/S0140-6736(17)32440-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(17)32440-6</ArticleId>
            <ArticleId IdType="pmc">PMC5901715</ArticleId>
            <ArticleId IdType="pubmed">28916367</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, et al.  Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015;16(8):928–936. doi: 10.1016/S1470-2045(15)00086-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(15)00086-8</ArticleId>
            <ArticleId IdType="pmc">PMC4648090</ArticleId>
            <ArticleId IdType="pubmed">26115797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE, et al.  Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473–2483. doi: 10.1056/NEJMoa1104390.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1104390</ArticleId>
            <ArticleId IdType="pubmed">22204724</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, et al.  ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484–96. doi: 10.1056/NEJMoa1103799.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1103799</ArticleId>
            <ArticleId IdType="pubmed">22204725</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>du Bois A, Floquet A, Kim JW, Rau J, del Campo JM, Friedlander M, Pignata S, Fujiwara K, Vergote I, Colombo N, et al.  Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol. 2014;32(30):3374–3382. doi: 10.1200/JCO.2014.55.7348.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2014.55.7348</ArticleId>
            <ArticleId IdType="pubmed">25225436</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, Rimel BJ, Buss MK, Nattam SR, Hurteau J, et al.  Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer. Ann Oncol. 2019;30(4):551–557. doi: 10.1093/annonc/mdz018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdz018</ArticleId>
            <ArticleId IdType="pmc">PMC6503628</ArticleId>
            <ArticleId IdType="pubmed">30753272</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ledermann JA, Embleton AC, Raja F, Perren TJ, Jayson GC, Rustin GJS, Kaye SB, Hirte H, Eisenhauer E, Vaughan M, et al.  Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;387(10023):1066–1074. doi: 10.1016/S0140-6736(15)01167-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(15)01167-8</ArticleId>
            <ArticleId IdType="pubmed">27025186</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vergote I, Scambia G, O'Malley DM, Van Calster B, Park SY, Del Campo JM, Meier W, Bamias A, Colombo N, Wenham RM, et al.  Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019;20(6):862–876. doi: 10.1016/S1470-2045(19)30178-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(19)30178-0</ArticleId>
            <ArticleId IdType="pubmed">31076365</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C. ESMO Guidelines Working Group. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv259. doi: 10.1093/annonc/mdy157.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdy157</ArticleId>
            <ArticleId IdType="pubmed">30285216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, Okamoto A, Moore KN, Efrat Ben-Baruch N, Werner TL, et al.  Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. N Engl J Med. 2019;381(25):2403–2415. doi: 10.1056/NEJMoa1909707.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1909707</ArticleId>
            <ArticleId IdType="pmc">PMC6941439</ArticleId>
            <ArticleId IdType="pubmed">31562800</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gershenson DM, Bodurka DC, Coleman RL, Lu KH, Malpica A, Sun CC. Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum. J Clin Oncol. 2017;35(10):1103–1111. doi: 10.1200/JCO.2016.71.0632.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2016.71.0632</ArticleId>
            <ArticleId IdType="pmc">PMC5455356</ArticleId>
            <ArticleId IdType="pubmed">28221866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gershenson DM, Sun CC, Iyer RB, Malpica AL, Kavanagh JJ, Bodurka DC, Schmeler K, Deavers M. Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol. 2012;125(3):661–666. doi: 10.1016/j.ygyno.2012.02.037.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ygyno.2012.02.037</ArticleId>
            <ArticleId IdType="pmc">PMC4405157</ArticleId>
            <ArticleId IdType="pubmed">22406638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kitawaki J, Noguchi T, Yamamoto T, Yokota K, Maeda K, Urabe M, Honjo H. Immunohistochemical localisation of aromatase and its correlation with progesterone receptors in ovarian epithelial tumours. Anticancer Res. 1996;16(1):91–97.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8615676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gibson L, Lawrence D, Dawson C, Bliss J. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst Rev. 2009;2009(4):CD003370. doi: 10.1002/14651858.CD003370.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/14651858.CD003370</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muss HB, Case LD, Atkins JN, Bearden JD, 3rd, Cooper MR, Cruz JM, Jackson DV, Jr, O'Rourke MA, Pavy MD, Powell BL, et al.  Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study. J Clin Oncol. 1994;12(8):1630–1638. doi: 10.1200/JCO.1994.12.8.1630.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.1994.12.8.1630</ArticleId>
            <ArticleId IdType="pubmed">8040675</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Early Breast Cancer Trialists' Collaborative Group (EBCTCG)  Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386(10001):1341–1352. doi: 10.1016/S0140-6736(15)61074-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(15)61074-1</ArticleId>
            <ArticleId IdType="pubmed">26211827</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wong ZW, Ellis MJ. First-line endocrine treatment of breast cancer: aromatase inhibitor or antioestrogen? Br J Cancer. 2004;90(1):20–25. doi: 10.1038/sj.bjc.6601508.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.bjc.6601508</ArticleId>
            <ArticleId IdType="pmc">PMC2395329</ArticleId>
            <ArticleId IdType="pubmed">14710200</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sasano H, Sato S, Ito K, Yajima A, Nakamura J, Yoshihama M, Ariga K, Anderson TJ, Miller WR. Effects of aromatase inhibitors on the pathobiology of the human breast, endometrial and ovarian carcinoma. Endocr Relat Cancer. 1999;6(2):197–204. doi: 10.1677/erc.0.0060197.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1677/erc.0.0060197</ArticleId>
            <ArticleId IdType="pubmed">10731109</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Langdon SP, Gourley C, Gabra H, Stanley B. Endocrine therapy in epithelial ovarian cancer. Expert Rev Anticancer Ther. 2017;17(2):109–117. doi: 10.1080/14737140.2017.1272414.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/14737140.2017.1272414</ArticleId>
            <ArticleId IdType="pubmed">27967255</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bowman A, Gabra H, Langdon SP, Lessells A, Stewart M, Young A, Smyth JF. CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup. Clin Cancer Res. 2002;8(7):2233–2239.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12114425</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smyth JF, Gourley C, Walker G, MacKean MJ, Stevenson A, Williams AR, Nafussi AA, Rye T, Rye R, Stewart M, McCurdy J, Mano M, Reed N, McMahon T, Vasey P, Gabra H, Langdon SP. Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients. Clin Cancer Res. 2007;13(12):3617–3622. doi: 10.1158/1078-0432.CCR-06-2878.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-06-2878</ArticleId>
            <ArticleId IdType="pubmed">17575226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heinzelmann-Schwarz V, Knipprath Mészaros A, Stadlmann S, Jacob F, Schoetzau A, Russell K, Friedlander M, Singer G, Vetter M. Letrozole may be a valuable maintenance treatment in high-grade serous ovarian cancer patients. Gynecol Oncol. 2018;148(1):79–85. doi: 10.1016/j.ygyno.2017.10.036.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ygyno.2017.10.036</ArticleId>
            <ArticleId IdType="pubmed">29157627</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Knipprath- Mészaros A, Heinzelmann-Schwarz V, Vetter M. Endocrine Therapy in Epithelial Ovarian Cancer (EOC) New Insights in an Old Target. Mini Rev J Cancer Clin Trials. 2018;3:2. doi: 10.4172/2577-0535.1000144.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4172/2577-0535.1000144</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lindemann K, Gibbs E, Åvall-Lundqvist E, dePont CR, Woie K, Kalling M, Auranen A, Grenman S, Hoegberg T, Rosenberg P. Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist) Br J Cancer. 2017;116(4):455–463. doi: 10.1038/bjc.2016.435.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/bjc.2016.435</ArticleId>
            <ArticleId IdType="pmc">PMC5318972</ArticleId>
            <ArticleId IdType="pubmed">28118323</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morgan RJ, Jr, Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Behbakht K, Chen LM, Copeland L, Crispens MA, DeRosa M, Dorigo O, et al.  Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016;14(9):1134–63. doi: 10.6004/jnccn.2016.0122.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.6004/jnccn.2016.0122</ArticleId>
            <ArticleId IdType="pubmed">27587625</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dickler MN, Barry WT, Cirrincione CT, Ellis MJ, Moynahan ME, Innocenti F, Hurria A, Rugo HS, Lake DE, Hahn O, et al.  Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance) J Clin Oncol. 2016;34(22):2602–2609. doi: 10.1200/JCO.2015.66.1595.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2015.66.1595</ArticleId>
            <ArticleId IdType="pmc">PMC5012690</ArticleId>
            <ArticleId IdType="pubmed">27138575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Plummer R, Verheul HM, De Vos FYFL, Leunen K, Molife LR, Rolfo C, Grundtvig-Sørensen P, De Grève J, Rottey S, Jerusalem G, et al.  Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours. Adv Ther. 2018;35(11):1945–1964. doi: 10.1007/s12325-018-0804-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12325-018-0804-z</ArticleId>
            <ArticleId IdType="pubmed">30324586</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paleari L, Gandini S, Provinciali N, Puntoni M, Colombo N, DeCensi A. Clinical benefit and risk of death with endocrine therapy in ovarian cancer: A comprehensive review and meta-analysis. Gynecol Oncol. 2017;146(3):504–513. doi: 10.1016/j.ygyno.2017.06.036.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ygyno.2017.06.036</ArticleId>
            <ArticleId IdType="pubmed">28705409</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bosse T, Nout RA, Stelloo E, Dreef E, Nijman HW, Jürgenliemk-Schulz IM, Jobsen JJ, Creutzberg CL, Smit VT. L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: pooled PORTEC trial results. Eur J Cancer. 2014;50(15):2602–2610. doi: 10.1016/j.ejca.2014.07.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejca.2014.07.014</ArticleId>
            <ArticleId IdType="pubmed">25126672</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soovares P, Pasanen A, Bützow R, Lassus H. L1CAM expression associates with poor outcome in endometrioid, but not in clear cell ovarian carcinoma. Gynecol Oncol. 2017;146(3):615–622. doi: 10.1016/j.ygyno.2017.06.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ygyno.2017.06.010</ArticleId>
            <ArticleId IdType="pubmed">28625395</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsoi M, Morin M, Rico C, Johnson RL, Paquet M, Gévry N, Boerboom D. Lats1 and Lats2 are required for ovarian granulosa cell fate maintenance. FASEB J. 2019;33(10):10819–10832. doi: 10.1096/fj.201900609R.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1096/fj.201900609R</ArticleId>
            <ArticleId IdType="pmc">PMC6766663</ArticleId>
            <ArticleId IdType="pubmed">31268774</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu B, Sun D, Wang Z, Weng H, Wu D, Zhang X, Zhou Y, Hu W. Expression of LATS family proteins in ovarian tumors and its significance. Hum Pathol. 2015;46(6):858–867. doi: 10.1016/j.humpath.2015.02.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.humpath.2015.02.012</ArticleId>
            <ArticleId IdType="pubmed">25841306</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schlumbrecht MP, Xie SS, Shipley GL, Urbauer DL, Broaddus RR. Molecular clustering based on ERα and EIG121 predicts survival in high-grade serous carcinoma of the ovary/peritoneum. Mod Pathol. 2011;24(3):453–462. doi: 10.1038/modpathol.2010.211.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/modpathol.2010.211</ArticleId>
            <ArticleId IdType="pmc">PMC3058634</ArticleId>
            <ArticleId IdType="pubmed">21102415</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gaillard SL, Andreano KJ, Gay LM, Steiner M, Jorgensen MS, Davidson BA, Havrilesky LJ, Alvarez Secord A, Valea FA, Colon-Otero G, et al.  Constitutively active ESR1 mutations in gynecologic malignancies and clinical response to estrogen-receptor directed therapies. Gynecol Oncol. 2019;154(1):199–206. doi: 10.1016/j.ygyno.2019.04.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ygyno.2019.04.010</ArticleId>
            <ArticleId IdType="pubmed">30987772</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodriguez-Freixinos V, Ruiz-Pace F, Fariñas-Madrid L, Garrido-Castro AC, Villacampa G, Nuciforo P, Vivancos A, Dienstmann R, Oaknin A. Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer. ESMO Open. 2019;4(2):e000444. doi: 10.1136/esmoopen-2018-000444.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/esmoopen-2018-000444</ArticleId>
            <ArticleId IdType="pmc">PMC6435251</ArticleId>
            <ArticleId IdType="pubmed">30962959</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jacob F, Alam S, Konantz M, Liang CY, Kohler RS, Everest-Dass AV, Huang YL, Rimmer N, Fedier A, Schötzau A, et al.  Transition of Mesenchymal and Epithelial Cancer Cells Depends on α1-4 Galactosyltransferase-Mediated Glycosphingolipids. Cancer Res. 2018;78(11):2952–2965. doi: 10.1158/0008-5472.CAN-17-2223.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-17-2223</ArticleId>
            <ArticleId IdType="pubmed">29572228</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, Rimel B, Buss MK, Nattam S, Hurteau J, et al.  Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol. 2014;15(11):1207–1214. doi: 10.1016/S1470-2045(14)70391-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(14)70391-2</ArticleId>
            <ArticleId IdType="pmc">PMC4294183</ArticleId>
            <ArticleId IdType="pubmed">25218906</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Banerjee S. The combination of VEGF inhibitors and anti-oestrogen therapies in breast cancer. Steroids. 2011;76(8):807–811. doi: 10.1016/j.steroids.2011.02.036.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.steroids.2011.02.036</ArticleId>
            <ArticleId IdType="pubmed">21439993</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Machin D, Campbell MJ, Tan SB, Tan SH. Sample Size Tables for Clinical Studies. Third Edition. 2009 doi: 10.1002/9781444300710.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/9781444300710</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lachin JM, Foulkes MA. Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. Biometrics. 1986;42(3):507–519. doi: 10.2307/2531201.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2307/2531201</ArticleId>
            <ArticleId IdType="pubmed">3567285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Royston P, Parmar MK. The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt. Stat Med. 2011;30(19):2409–2421. doi: 10.1002/sim.4274.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/sim.4274</ArticleId>
            <ArticleId IdType="pubmed">21611958</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sabbatini P. Consolidation therapy in ovarian cancer: a clinical update. Int J Gynecol Cancer. 2009;19(Suppl 2):S35–S39. doi: 10.1111/IGC.0b013e3181c14007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/IGC.0b013e3181c14007</ArticleId>
            <ArticleId IdType="pubmed">19955912</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sieh W, Köbel M, Longacre TA, Bowtell DD, deFazio A, Goodman MT, Høgdall E, Deen S, Wentzensen N, Moysich KB, et al.  Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol. 2013;14(9):853–862. doi: 10.1016/S1470-2045(13)70253-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(13)70253-5</ArticleId>
            <ArticleId IdType="pmc">PMC4006367</ArticleId>
            <ArticleId IdType="pubmed">23845225</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
